P1456: EARLY SAFETY AND CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MEASURABLE RESIDUAL DISEASE RECEIVING GTA002, AN OFF-THE-SHELF, EX VIVO-CULTURED ALLOGENEIC NK CELL PREPARATION. (23rd June 2022) - Heuser, M.; Fiedler, W.; Block, A.; de Leeuw, D. C.; van de Loosdrecht, A.; Astrid Tschan-Plessl, A.; Passweg, J.; Kloos, A.; Schwarzer, A.; Venturini, L.; Duru, A. D.; Pinkernell, K.; et al.